SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 21st, 2024 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 19, 2024, between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 21st, 2024 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 19, 2024, between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SIXTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 21st, 2024 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
This Sixth Amendment (“Sixth Amendment”) to Exclusive License Agreement effective as of August 2, 2024 (“Sixth Amendment Effective Date”) is by and between: EISAI INC., with its principal office at 200 Metro Blvd., Nutley, NJ 07110, United States of America (“Eisai”) and ALLARITY THERAPEUTICS, INC., with its principal office at 24 School Street, 2nd Floor, Boston MA 02108, together with its wholly-owned subsidiaries (“Allarity”) (formerly Oncology Venture A/S), with reference to the following:
